Acute Chlamydia pneumoniae and Mycoplasma pneumoniae infections in community-acquired pneumonia and exacerbations of COPD or asthma: Therapeutic considerations

F. Meloni, E. Paschetto, P. Mangiarotti, M. Crepaldi, M. Morosini, A. Bulgheroni, A. Fietta

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Rates of acute Chlamydia pneumoniae and Mycoplasma pneumoniae infections were determined in 115 adults hospitalized for community-acquired pneumonia (CAP), purulent exacerbations of COPD and acute exacerbations of bronchial asthma, by means of serology and molecular methods. Results were compared with those obtained in a matched control group. Common respiratory pathogens were isolated by cultures in 22.5% and 22.2% of CAP and exacerbated COPD patients, respectively. Cultures from exacerbated asthma patients were always negative. Serological and molecular evidence of current C. pneumoniae infection was obtained in 10.0%, 8.9% and 3.3% of CAP, COPD and asthma cases. The corresponding rates of acute M. pneumoniae infection were 17.5%, 6.7% and 3.3%, respectively. Finally, no difference was found between typical and atypical pathogen rates. These findings highlight the importance of taking into account C. pneumoniae and M. pneumoniae infections in guiding the choice of empirical antibacterial treatment for CAP and purulent exacerbations of COPD.

Original languageEnglish
Pages (from-to)70-76
Number of pages7
JournalJournal of Chemotherapy
Volume16
Issue number1
Publication statusPublished - Feb 2004

Fingerprint

Community-Acquired Infections
Chlamydophila pneumoniae
Mycoplasma pneumoniae
Chronic Obstructive Pulmonary Disease
Pneumonia
Asthma
Infection
Chlamydia Infections
Serology
Therapeutics
Research Design
Control Groups

Keywords

  • Antibiotic treatment
  • Asthma exacerbations
  • C. pneumoniae
  • CAP
  • COPD exacerbations
  • M. pneumoniae

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Microbiology (medical)

Cite this

Acute Chlamydia pneumoniae and Mycoplasma pneumoniae infections in community-acquired pneumonia and exacerbations of COPD or asthma : Therapeutic considerations. / Meloni, F.; Paschetto, E.; Mangiarotti, P.; Crepaldi, M.; Morosini, M.; Bulgheroni, A.; Fietta, A.

In: Journal of Chemotherapy, Vol. 16, No. 1, 02.2004, p. 70-76.

Research output: Contribution to journalArticle

@article{b3cbe43bc65741eca93c5da34fa196c0,
title = "Acute Chlamydia pneumoniae and Mycoplasma pneumoniae infections in community-acquired pneumonia and exacerbations of COPD or asthma: Therapeutic considerations",
abstract = "Rates of acute Chlamydia pneumoniae and Mycoplasma pneumoniae infections were determined in 115 adults hospitalized for community-acquired pneumonia (CAP), purulent exacerbations of COPD and acute exacerbations of bronchial asthma, by means of serology and molecular methods. Results were compared with those obtained in a matched control group. Common respiratory pathogens were isolated by cultures in 22.5{\%} and 22.2{\%} of CAP and exacerbated COPD patients, respectively. Cultures from exacerbated asthma patients were always negative. Serological and molecular evidence of current C. pneumoniae infection was obtained in 10.0{\%}, 8.9{\%} and 3.3{\%} of CAP, COPD and asthma cases. The corresponding rates of acute M. pneumoniae infection were 17.5{\%}, 6.7{\%} and 3.3{\%}, respectively. Finally, no difference was found between typical and atypical pathogen rates. These findings highlight the importance of taking into account C. pneumoniae and M. pneumoniae infections in guiding the choice of empirical antibacterial treatment for CAP and purulent exacerbations of COPD.",
keywords = "Antibiotic treatment, Asthma exacerbations, C. pneumoniae, CAP, COPD exacerbations, M. pneumoniae",
author = "F. Meloni and E. Paschetto and P. Mangiarotti and M. Crepaldi and M. Morosini and A. Bulgheroni and A. Fietta",
year = "2004",
month = "2",
language = "English",
volume = "16",
pages = "70--76",
journal = "Journal of Chemotherapy",
issn = "1120-009X",
publisher = "Maney Publishing",
number = "1",

}

TY - JOUR

T1 - Acute Chlamydia pneumoniae and Mycoplasma pneumoniae infections in community-acquired pneumonia and exacerbations of COPD or asthma

T2 - Therapeutic considerations

AU - Meloni, F.

AU - Paschetto, E.

AU - Mangiarotti, P.

AU - Crepaldi, M.

AU - Morosini, M.

AU - Bulgheroni, A.

AU - Fietta, A.

PY - 2004/2

Y1 - 2004/2

N2 - Rates of acute Chlamydia pneumoniae and Mycoplasma pneumoniae infections were determined in 115 adults hospitalized for community-acquired pneumonia (CAP), purulent exacerbations of COPD and acute exacerbations of bronchial asthma, by means of serology and molecular methods. Results were compared with those obtained in a matched control group. Common respiratory pathogens were isolated by cultures in 22.5% and 22.2% of CAP and exacerbated COPD patients, respectively. Cultures from exacerbated asthma patients were always negative. Serological and molecular evidence of current C. pneumoniae infection was obtained in 10.0%, 8.9% and 3.3% of CAP, COPD and asthma cases. The corresponding rates of acute M. pneumoniae infection were 17.5%, 6.7% and 3.3%, respectively. Finally, no difference was found between typical and atypical pathogen rates. These findings highlight the importance of taking into account C. pneumoniae and M. pneumoniae infections in guiding the choice of empirical antibacterial treatment for CAP and purulent exacerbations of COPD.

AB - Rates of acute Chlamydia pneumoniae and Mycoplasma pneumoniae infections were determined in 115 adults hospitalized for community-acquired pneumonia (CAP), purulent exacerbations of COPD and acute exacerbations of bronchial asthma, by means of serology and molecular methods. Results were compared with those obtained in a matched control group. Common respiratory pathogens were isolated by cultures in 22.5% and 22.2% of CAP and exacerbated COPD patients, respectively. Cultures from exacerbated asthma patients were always negative. Serological and molecular evidence of current C. pneumoniae infection was obtained in 10.0%, 8.9% and 3.3% of CAP, COPD and asthma cases. The corresponding rates of acute M. pneumoniae infection were 17.5%, 6.7% and 3.3%, respectively. Finally, no difference was found between typical and atypical pathogen rates. These findings highlight the importance of taking into account C. pneumoniae and M. pneumoniae infections in guiding the choice of empirical antibacterial treatment for CAP and purulent exacerbations of COPD.

KW - Antibiotic treatment

KW - Asthma exacerbations

KW - C. pneumoniae

KW - CAP

KW - COPD exacerbations

KW - M. pneumoniae

UR - http://www.scopus.com/inward/record.url?scp=1942487237&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1942487237&partnerID=8YFLogxK

M3 - Article

C2 - 15078002

AN - SCOPUS:1942487237

VL - 16

SP - 70

EP - 76

JO - Journal of Chemotherapy

JF - Journal of Chemotherapy

SN - 1120-009X

IS - 1

ER -